Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04970654 |
| Consolidated Lead Sponsor | Novo Nordisk |
| Therapeutic Condition Cohort | Endocrinology, Obesity, and Metabolic |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 110 participants (ACTUAL) |
| Registered Start Date | 2021-07-22 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| The Second Hospital of Anhui Medical University | Hefei, China | Open Hospital Dossier -> |
| Beijing Children's Hospital, Capital Medical University | Beijing, China | Open Hospital Dossier -> |
| The First Affiliated Hospital, Sun-Yat Sen University | Guangzhou, China | Open Hospital Dossier -> |
| The Second Xiangya Hospital of Central South University | Changsha, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.